60/30: 60% of the Morbidity-Associated Multiple Sclerosis Disease Burden Comes From the 30% of Persons With Higher Impairments.

Détails

Ressource 1Télécharger: 32210908_BIB_12570E9CE817.pdf (430.11 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_12570E9CE817
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
60/30: 60% of the Morbidity-Associated Multiple Sclerosis Disease Burden Comes From the 30% of Persons With Higher Impairments.
Périodique
Frontiers in neurology
Auteur⸱e⸱s
Kaufmann M., Puhan M.A., Salmen A., Kamm C.P., Manjaly Z.M., Calabrese P., Schippling S., Müller S., Kuhle J., Pot C., Gobbi C., Steinemann N., von Wyl V.
Collaborateur⸱rice⸱s
Swiss Multiple Sclerosis Registry (SMSR)
ISSN
1664-2295 (Print)
ISSN-L
1664-2295
Statut éditorial
Publié
Date de publication
2020
Peer-reviewed
Oui
Volume
11
Pages
156
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Résumé
Background: Multiple sclerosis (MS) is the most common chronic, non-traumatic, neurologic disease in young adults. While approximate values of the disease burden of MS are known, individual drivers are unknown. Objective: To estimate the age-, sex-, and disease severity-specific contributions to the disease burden of MS. Methods: We estimated the disease burden of MS using disability-adjusted life years (DALYs) following the Global Burden of Disease study (GBD) methodology. The data sources consisted of the Swiss MS Registry, a recent prevalence estimation, and the Swiss mortality registry. Results: The disease burden of MS in Switzerland in 2016 was 6,938 DALYs (95%-interval: 6,018-7,955), which corresponds to 97 DALYs per 100,000 adult inhabitants. Morbidity contributed 59% of the disease burden. While persons in an asymptomatic (EDSS-proxy 0) and mild (EDSS-proxy >0-3.5) disease stage represent 68.4% of the population, they make up 39.8% of the MS-specific morbidity. The remaining 60.2% of the MS-specific morbidity stems from the 31.6% of persons in a moderate (EDSS-proxy 4-6.5) or severe (EDSS-proxy ≥7) disease stage. Conclusions: Morbidity has a larger influence on the disease burden of MS than mortality and is shared in a ratio of 2:3 between persons in an asymptomatic/mild and moderate/severe disease stage in Switzerland. Interventions to reduce severity worsening in combination with tailored, symptomatic treatments are important future paths to lower the disease burden of MS.
Mots-clé
DALY, SMSR, burden, epidemiology, morbidity, mortality
Pubmed
Open Access
Oui
Création de la notice
01/04/2020 19:25
Dernière modification de la notice
15/01/2021 8:08
Données d'usage